Clinical Trial Update: Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of omalizumab in children aged 6 to less than 12 with moderate-to-severe allergic asthma; results were posted i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Xolair (omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Asthma | Phase 3 | Status: COMPLETED | Results posted: 2011-08-03